Rigel Pharmaceuticals

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs with hematologic disorders, cancer and rare immune diseases.
Rigel Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Rigel Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Rigel Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Rigel Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Rigel Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Rigel Pharmaceuticals assets
Rigel Pharmaceuticals cash flows

Rigel Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
RIGL:USRigel PharmaceuticalsCommon share-US7665596034$1.08
Rigel Pharmaceuticals news
04.05.2022
The loss of Rigel Pharmaceuticals under GAAP for the 3 months of 2022 was $27.445 million, against a profit of $39.5 million in the previous year. Revenue decreased 4.8 times to $16.735 million from $81.018 million the year before.
Source: {source} pictogram rigel.com
Pictogram next
02.03.2022
Rigel Pharmaceuticals' GAAP loss for 2021 was $17.914 million, down 39.8% from $29.744 million in the previous year. Revenue increased 37.4% to $149.236 million from $108.621 million a year earlier.
Source: {source} pictogram rigel.com
Pictogram next
03.11.2021
Rigel Pharmaceuticals reported a GAAP net profit of $4.727 million for 9M 2021, compared to a loss of $10.507 million in the previous year. Revenue increased 42.9% to $128.827 million from $90.171 million a year earlier.
Source: {source} pictogram rigel.com
Pictogram next
04.08.2021
Rigel Pharmaceuticals' GAAP net income for the six months of 2021 was $25.679 million, up 7 times from $3.667 million in the previous year. Revenue increased 49.5% to $107.284 million from $71.782 million a year earlier.
Source: {source} pictogram rigel.com
Pictogram next
All Rigel Pharmaceuticals news
General information
Company nameRigel Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
Mailing address1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080
Websitewww.rigel.com
Information disclosurewww.sec.gov